Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for prostate cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Radiolabelled choline versus PSMA PET/CT in prostatecancer restaging: a meta-analysis. Both radiolabelled choline and prostate specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) could be used in patients with biochemical recurrent prostatecancer (BRPCa). We aimed to perform a meta-analysis about the head-to-head comparison of detection rate (DR) between these methods in BRPCa. A comprehensive literature search of studies listed in PubMed/MEDLINE, EMBASE (...) and Cochrane library databases through October 2018 and regarding the head-to-head comparison of DR between radiolabelled choline and PSMA PET/CT in BRPCa was carried out. Overall pooled DR was calculated on a per patient-based analysis; subgroup analyses taking into account different prostate-specific antigen (PSA) cut-off values were performed. Five studies (257 BRPCa patients) were included. The meta-analysis provided the following overall DR: 56% [95% confidence interval (95% CI): 37-75
The incidence proportion of erectile dysfunction in patients treated with cryotherapy for prostatecancer: a meta-analysis. With the maturity of cryotherapy for prostatecancer, the complications after operation are also decreasing, which can improve the prognosis of patients. However, erectile dysfunction (ED) is still one of the main complications after cryotherapy. Therefore, we performed a meta-analysis to evaluate the incidence of erectile dysfunction in patients after cryotherapy.A (...) identified, however, only 12 used validated outcome measures and met inclusion criteria. A total of 12 studies were included in this meta-analysis. Overall, the results of this meta-analysis showed that the pooled incidence rate of ED was 0.27 (95% CI 0.26-0.28) which means that the incidence rate of ED after cryotherapy for prostatecancer was not high, but we still found that there are great heterogeneity between the 12 articles. By subgroup analysis, we found a statistically significant incidence rate
Anemia is associated with poor outcomes of metastatic castration-resistant prostatecancer, a systematic review and meta-analysis. Androgen deprivation therapy (ADT) was an important management for metastatic prostatecancer. However, patients would finally progress to the metastatic castration-resistant prostatecancer (mCRPC) and lose sensitivity to ADT. In addition to lower testosterone level, ADT could cause anemia, which might impair the chemotherapy efficiency and worsen the outcomes (...) of cancer patients. However, inconsistent results were found between anemia and mCRPC prognosis. Our study was the first systematic review to evaluate the influence of anemia in mCRPC prognosis. Thirteen studies with 6,484 samples were involved in this meta-analysis. We found anemia would worsen the Overall survival (OS) of mCRPC patients in both prognostic designed studies (HR = 1.55, 95% CI = 1.24-1.94) and retrospective designed studies (HR = 1.82, 95% CI = 1.52-2.18). Prognostic analyses also
Long-Term Clinical Outcomes of Radical Prostatectomy versus Watchful Waiting in Localized ProstateCancer Patients: A Systematic Review and Meta-Analysis. The present study aimed to compare the long-term clinical and functional outcomes of patients with clinically localized prostatecancer treated with radical prostatectomy compared to the watchful waiting.PubMed, Cochrane Central Register of Controlled Trials and reference lists of relevant marker studies were scrutinized from inception to Jan (...) no significant effect on all-cause mortality at 12-year follow-up. However, radical prostatectomy had significant effect on reducing prostate-cause mortality at 12-year follow-up. We found significant lower prostate-cause mortality in patients with PSA>10 and GS≥7 scores who had undergone radical prostatectomy compared with patients in watchful waiting group. In addition, younger patients undergoing surgery developed lower distant metastases rate compared to another approach. Watchful waiting had
A Systematic Review and Meta-Analysis of ProstateCancer Utility Values of Patients and Partners Between 2007 and 2016. Background. There is widespread agreement that both the length and quality of life matter when assessing new technologies and/or models of care in the treatment for cancer patients. Quality of life for partners/carers also matters, particularly for prostatecancer. Purpose. This systematic review aims to provide up-to-date utility values along the prostatecancer care (...) . Study selection terms included health-related quality of life, prostatecancer, and partners or carers. Data Extraction. The authors identified articles published between 2007 and 2016 that provided health state utility values, with statistical uncertainty, for men with or at risk of prostatecancer and/or their partner/carers. Data Synthesis and Results. Study quality and generalizability of utilities was evaluated and meta-analysis conducted against prespecified criteria. From 906 original
Occupational Risk Factors for ProstateCancer: A Meta-analysis. Prostatecancer is the second most common cancer in men worldwide. There are many occupational factors that have been suggested to cause prostatecancer. Our aim was to evaluate the evidence for causality by a literature review of occupational factors. We searched literature in Medline and SCOPUS from 1966 to June 30, 2015 to identify occupational risk factors for prostatecancer. The following risk factors were selected: farmers (...) with 90,688 prostatecancer cases. Significantly increased risks were observed for the following occupational exposures: pesticides (metaRR = 1.15, 95% confidence interval [CI] = 1.01-1.32; I2 = 84%), and specifically group of organochlorine pesticides (meta relative risk [metaRR] = 1.08, 95% CI = 1.03-1.14; I2 = 0%), chromium (metaRR = 1.19, 95% CI = 1.07-1.34; I2 = 31%), shift work (metaRR = 1.25, 95% CI = 1.05-1.49; I2 = 78%) and pilots (metaRR = 1.41, 95% CI = 1.02-1.94; I2 = 63%) and occupational
The effect of additional chemotherapy on high-risk prostatecancer: a systematic review and meta-analysis. The role of additional chemotherapy in the treatment of high-risk prostatecancer (PCa) remains a controversy. This meta-analysis aimed to investigate the effect of additional chemotherapy on high-risk PCa.Randomized controlled trials (RCTs) about additional chemotherapy for high-risk PCa were searched in PubMed, MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials. We
Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials. Hormonal therapies for receptor positive-breast and prostatecancer patients have shown clinical efficacy but also several side effects including osteoporosis, loss of bone mass and increased fracture risk. Denosumab represents an anti RANKL (receptor activator of nuclear factor-kB ligand) monoclonal anti-body acting as inhibitor (...) of osteoclasts formation, function, and survival, then increasing bone mass. Herein, we performed a systematic review and meta-analysis of randomized controlled trials (RCTs) to evaluate the role of Denosumab in saving bone health in prostate and breast cancer patients receiving respectively androgen deprivation therapy and adjuvant endocrine therapy. Moreover, selected patients have to be treated with Denosumab at the dose of 60 mg every six month or placebo. Outcomes studied included the bone mass density
Shared decision making for men facing prostatecancer treatment: a systematic review of randomized controlled trials. Aims: To synthesize the empirical evidence on the effectiveness of shared decision making (SDM) compared to usual care for prostatecancer (PC) treatment. Methods and results: A systematic review of academic (MEDLINE, EMBASE, Cochrane Library, CINHAL, PsychINFO, and Scopus) and grey (clinicaltrials.gov, WHO trial search, meta-Register ISRCTN, Google Scholar, opengrey
Association of glutathione-S-transferase p1 gene promoter methylation and the incidence of prostatecancer: a systematic review and meta-analysis. Some studies have shown that the methylation status of the GSTP1 gene promoter is related to the incidence of prostatecancer, but this finding is still controversial. The aim of this study was to evaluate the association between glutathione-S-transferase p1 (GSTP1) promoter methylation and the incidence of prostate cancer.The Medline, Embase, Web (...) of Science, and Cochrane CENTRAL databases were searched from their inception to February 22, 2019. According to the inclusion criteria, studies of the association between the methylation status of the GSTP1 gene promoter and prostatecancer were included. The difference in the incidence of GSTP1 promoter methylation in tissues, blood, or urine between patients with prostatecancer and those without prostatecancer were compared, and the results were expressed as the odds ratio (OR) and 95% confidence
differences between intervention and no-training control groups. Results: We identified 8,521 publications through the search of the following key words: prostatecancer, prostatetumor, prostatecarcinoma, prostateneoplasm, exercise, and training. Out of these studies, seven randomized controlled trials met the inclusion criteria and where included in the analysis. No significant mean differences for changes in lean mass were observed between the intervention and control groups (0.49 kg, 95% CI: -0.76 (...) Supervised Physical Training Enhances Muscle Strength but Not Muscle Mass in ProstateCancer Patients Undergoing Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis. Introduction: Androgen deprivation therapy (ADT) is considered the basic treatment for advanced prostatecancer, but it is highly associated with detrimental changes in muscle mass and muscle strength. The aim of this meta-analysis was to investigate the effects of supervised physical training on lean mass
Role of percutaneous nephrostomy in end of life prostatecancer patients: a systematic review of the literature. Prostatecancer is the most common cancer amongst men in the UK. Treatments for malignant ureteric obstruction consist of percutaneous nephrostomy, ureteric stent insertion, or occasionally other forms of urinary diversion. Our aim was to look at the outcomes of percutaneous nephrostomy (PCN) in patients with advanced prostatecancer and to look at the impact on patient's general (...) health, quality of life, life expectancy and complications after PCN insertion.A systematic review of the literature was done for all prospective English language articles on PCN in patients with prostatecancer using PubMed, MEDLINE, EMBASE, Scopus, CINAHL, Cochrane library, Clinicaltrials.gov, Google Scholar and individual urological journals from inception to August 2017. While studies involving prostatecancer patients were included, studies on all other mixed pelvic malignancies were
between TMPRSS2 fusion gene, its single nucleotide polymorphisms and prostatecancer. The primary outcome was prostatecancer defined by histology of the tumor coming from transrectal ultrasound guided biopsy, transurethral resection of the prostate or radical prostatectomy. We assessed the risk of bias with QUADAS2 and performed a meta-analysis with Stata 14.We found 241 records with the search strategies. After duplicates were removed, 18 studies were included in qualitative analysis and 15 studies (...) Association between TMPRSS2:ERG fusion gene and the prostatecancer: systematic review and meta-analysis. To identify the association between the TMPRSS2:ERG fusion gene, their variants and the onset of localized prostate cancer.A systematic search strategy was carried out through MEDLINE, EMBASE, LILACS, CENTRAL and unpublished literature. We included randomized control trials, cohort, case-control and cross-sectional studies that involved patients >18 years-old assessing the association
Detection rates of recurrent prostatecancer: The aim of this work was to assess the use of prostate-specific membrane antigen (PSMA)-labelled radiotracers in detecting the recurrence of prostatecancer. PSMA is thought to have higher detection rates when utilized in positron emission tomography (PET)/computed tomography (CT) scans, particularly at lower prostate-specific antigen (PSA) levels, compared with choline-based scans.A systematic review was conducted comparing choline and PSMA PET/CT (...) scans in patients with recurrent prostatecancer following an initial curative attempt. The primary outcomes were overall detection rates, detection rates at low PSA thresholds, difference in detection rates and exclusive detection rates on a per-person analysis. Secondary outcome measures were total number of lesions, exclusive detection by each scan on a per-lesion basis and adverse side effects.Overall detection rates were 79.8% for PSMA and 66.7% for choline. There was a statistically
Effect of Androgen-Deprivation Therapy on Bone Mineral Density in Patients with ProstateCancer: A Systematic Review and Meta-Analysis. We aimed to evaluate the change in bone mineral density (BMD) in patients with prostatecancer (PCa) receiving androgen deprivation therapy (ADT) compared to those with PCa or other urologic conditions not receiving ADT. Literature searches were conducted throughout October 2018. The eligibility of each study was assessed according to Preferred Reporting Items
SAMD5 mRNA was overexpressed in prostatecancer and can predict biochemical recurrence after radical prostatectomy. To identify a novel biomarker that can predict biochemical recurrence (BCR) after radical prostatectomy.The gene expression profile of SAMD5 in prostatecancer was explored based on the oncomine database and The Cancer Genomic Atlas (TCGA). The follow-up information and clinical pathologic variables were extracted from the following cohort study: TCGA_prostate carcinoma (...) . And then, survival analysis was conducted using the Kaplan-Meier plot and Cox's proportional hazard regression model. Furthermore, another independent cohort study: Taylor prostate, was also acquired to validate the predictive effect of SAMD5 on BCR. In addition, the expression profile of SAMD5 in other cancer types was investigated using TCGA dataset.SAMD5 mRNA was shown to be up-regulated in multiple microarray datasets of prostatecancer with the strict statistic criteria: p < 0.01 and fold change ≥ 2
MicroRNA-21 and microRNA-30c as diagnostic biomarkers for prostatecancer: a meta-analysis. Prostatecancer (PCa) is the second leading cause of cancer death in men. Several articles have reported that microRNA-21 (miR-21) and microRNA-30c (miR-30c) have diagnostic values for PCa, but the results are inconclusive. In order to precisely assess the diagnostic values of miR-21 and miR-30c for PCa, this meta-analysis is performed.Articles were searched in the databases of PubMed, Embase, and Web
Model-based cost-effectiveness analysis of external beam radiation therapy for the treatment of localized prostatecancer: a systematic review. External beam radiotherapy is the recommended but expensive treatment option for localized prostatecancer. Prostatecancer is the most common cancer in men worldwide. A cost-effectiveness study is needed given the excessive cost of radiotherapy treatment and the high prevalence of prostatecancer. The aim of this systematic review was to assess (...) -effective.There are limited number of studies exist on the cost effectiveness of radiation therapy options for the treatment of localize prostatecancer across Europe. Most studies are originated from the US Medicare payer Perspective. Further research is need that investigate the cost effectiveness of these radiation therapy options from the societal perspective in Europe.
cancer occurrence in Iran, it is recommended that preventive measures be taken against this disease by health policymakers. Also, more epidemiological studies are needed to better find out the pattern of prostatecancer among Iranian populations. (...) A systematic review and meta-analysis on incidence of prostatecancer in Iran. Background: Prostatecancer is a global health concern. In Iran, its epidemiology is not precisely recognized. We aimed to evaluate incidence of prostatecancer among Iranian populations. Methods: In this systematic review, we searched the databases PubMed, Web of Sciences, Scopus and Google Scholar for English studies and the databases Magiran, Scientific information Database, IranMedex and IranDoc for Persian
Cytokines expression levels from tissue, plasma or serum as promising clinical biomarkers in adenocarcinoma of the prostate: a systematic review of recent findings. Prostatecancer (PC) is a common cancer (excluding non-melanoma skin cancer) in men in many parts of the world, although incidence and mortality rates vary significantly by population. In current medical practice, prognostic markers for PC include the presenting serum prostate-specific antigen (PSA) level, tumour Gleason score (GS (...) electronic databases: PubMed, Medline, and Google Scholar. An additional search was carried out through cross-check on a bibliography of selected articles. After the selection process made by two of the authors, 19 articles met the inclusion criteria and were included in the systematic review. Results from previous studies identified elevated levels of cytokines have been reported in several types of cancers and have sometimes correlated with disease progression or prognosis. Elevated levels of cytokine